Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Diabetes is defined by its association with hyperglycemia-specific microvascular complications; however, it also imparts a two- to fourfold risk of cardiovascular disease (CVD). Although microvascular complications can lead to significant morbidity and premature mortality, by far the greatest cause of death in people with diabetes is CVD. Results from randomized controlled trials have demonstrated conclusively that the risk of microvascular complications can be reduced by intensive glycemic control in patients with type 1 (1,2) and type 2 diabetes (3–5). In the Diabetes Control and Complications Trial (DCCT), there was an ∼60% reduction in development or progression of diabetic retinopathy, nephropathy, and neuropathy between the intensively treated group (goal A1C <6.05%, mean achieved A1C ∼7%) and the standard group (A1C ∼9%) over an average of 6.5 years. The relationship between glucose control (as reflected by the mean on-study A1C value) and risk of complications was log-linear and extended down to the normal A1C range (<6%) with no threshold noted. In the UK Prospective Diabetes Study (UKPDS), participants newly diagnosed with type 2 diabetes were followed for 10 years, and intensive control (median A1C 7.0%) was found to reduce the overall microvascular complication rate by 25% compared with conventional treatment (median A1C 7.9%). Here, too, secondary analyses showed a continuous relationship between the risk of microvascular complications and glycemia extending into the normal range of A1C, with no glycemic threshold. On the basis of these two large controlled trials, along with smaller studies and numerous epidemiologic reports, the consistent findings related to microvascular risk reduction with intensive glycemic control have led the American Diabetes Association (ADA) to recommend an A1C goal of <7% for most adults with diabetes (6), recognizing that more or less stringent goals may be appropriate for certain patients. Whereas many epidemiologic studies and meta-analyses …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, severe hypoglycemia may also be a marker of vulnerability, without any direct causal contribution to the increased mortality (72).”
From Hypoglycemia (2018) · cites this paper as [72]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Research works printed but not linked: 1
- Duckworth W, Abraira C, Moritz T, Reda D, Emannele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vikek ME, Henderson WG, Huang GD: Intensive glucose control and complications in American veterans with type 2 diabetes. N Engl J Med. In press
Cited by
Items 101–200 of 879
The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence
Nordin, C. (2010) · Diabetologia · doi:10.1007/s00125-010-1752-6 · Cited by 157
Glycemic Control and Cardiovascular Disease in 7,454 Patients With Type 1 Diabetes
Eeg-Olofsson, K., Cederholm, J., Nilsson, P. M., Zethelius, B., Svensson, A.-M., Gudbjörnsdóttir, S., & Eliasson, B. (2010) · Diabetes Care · doi:10.2337/dc10-0398 · Cited by 142
Ji, L.-N., Lu, J.-M., Guo, X.-H., Yang, W.-Y., Weng, J.-P., Jia, W.-P., Zou, D.-J., Zhou, Z.-G., Yu, D.-M., Liu, J., et al. (2013) · BMC Public Health · doi:10.1186/1471-2458-13-602 · Cited by 142
Death during intensive glycemic therapy of diabetes: mechanisms and implications
Cryer, P. E. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.08.008 · Cited by 137
Midlife Vascular Risk Factors and Alzheimer's Disease: Evidence from Epidemiological Studies
Tolppanen, A.-M., Solomon, A., Soininen, H., & Kivipelto, M. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120802 · Cited by 136
2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation
Барбараш, О. Л., Duplyakov, D. V., Zateischikov, D. A., Панченко, Е. П., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Sa, A., Alekyan, B. G., Викторович, А. М., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4449 · Cited by 149
Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach
Kedia (2011) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s20633 · Cited by 131
Tuleta, I., & Frangogiannis, N. G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113904 · Cited by 150
Rothschild, S. K., Martin, M. A., Swider, S. M., Tumialán Lynas, C. M., Janssen, I., Avery, E. F., & Powell, L. H. (2014) · American Journal of Public Health · doi:10.2105/ajph.2013.301439 · Cited by 129
Miller, M. E., Williamson, J. D., Gerstein, H. C., Byington, R. P., Cushman, W. C., Ginsberg, H. N., Ambrosius, W. T., Lovato, L., Applegate, W. B., & for the ACCORD Investigators (2014) · Diabetes Care · doi:10.2337/dc13-1545 · Cited by 129
Exercise therapy in Type 2 diabetes
Praet, S. F. E., & van Loon, L. J. C. (2009) · Acta Diabetologica · doi:10.1007/s00592-009-0129-0 · Cited by 128
Is Glucose Control Important for Prevention of Cardiovascular Disease in Diabetes?
Mannucci, E., Dicembrini, I., Lauria, A., & Pozzilli, P. (2013) · Diabetes Care · doi:10.2337/dcs13-2018 · Cited by 127
Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of <7% in Type 2 Diabetes
Giugliano, D., Maiorino, M. I., Bellastella, G., Chiodini, P., Ceriello, A., & Esposito, K. (2011) · Diabetes Care · doi:10.2337/dc10-1710 · Cited by 127
The effects of yoga among adults with type 2 diabetes: A systematic review and meta-analysis
Thind, H., Lantini, R., Balletto, B. L., Donahue, M. L., Salmoirago-Blotcher, E., Bock, B. C., & Scott-Sheldon, L. A. J. (2017) · Preventive Medicine · doi:10.1016/j.ypmed.2017.08.017 · Cited by 124
Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes
Herman, M. E., O’Keefe, J. H., Bell, D. S. H., & Schwartz, S. S. (2017) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2017.09.001 · Cited by 130
Daly, A. B., Boughton, C. K., Nwokolo, M., Hartnell, S., Wilinska, M. E., Cezar, A., Evans, M. L., & Hovorka, R. (2023) · Nature Medicine · doi:10.1038/s41591-022-02144-z · Cited by 120
Barriers and facilitators to starting insulin in patients with type 2 diabetes: a systematic review
Ng, C. J., Lai, P. S. M., Lee, Y. K., Azmi, S. A., & Teo, C. H. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12691 · Cited by 120
Bramlage, P., Gitt, A. K., Binz, C., Krekler, M., Deeg, E., & Tschöpe, D. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-122 · Cited by 119
Latres, E., Finan, D. A., Greenstein, J. L., Kowalski, A., & Kieffer, T. J. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.007 · Cited by 117
Palta, P., Huang, E. S., Kalyani, R. R., Golden, S. H., & Yeh, H.-C. (2017) · Diabetes Care · doi:10.2337/dci16-0042 · Cited by 116
2011 Clinical Practice Guidelines for Type 2 Diabetes in Korea
Ko, S.-H., Kim, S.-R., Kim, D.-J., Oh, S.-J., Lee, H.-J., Shim, K.-H., Woo, M.-H., Kim, J.-Y., Kim, N.-H., Kim, J.-T., et al. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.5.431 · Cited by 114
Wild, S. H., Hanley, J., Lewis, S. C., McKnight, J. A., McCloughan, L. B., Padfield, P. L., Parker, R. A., Paterson, M., Pinnock, H., Sheikh, A., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002098 · Cited by 115
Giorgino, F., Leonardini, A., & Laviola, L. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12044 · Cited by 118
Hydrogel optical fibers for continuous glucose monitoring
Elsherif, M., Hassan, M. U., Yetisen, A. K., & Butt, H. (2019) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2019.05.002 · Cited by 108
New forms of insulin and insulin therapies for the treatment of type 2 diabetes
Cahn, A., Miccoli, R., Dardano, A., & Prato, S. D. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00097-2 · Cited by 114
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Price, D. L., Chen, R., Udell, J., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.08.006 · Cited by 106
Yale, J.-F., Paty, B., & Senior, P. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.010 · Cited by 105
Trends in the Risk for Coronary Heart Disease Among Adults With Diagnosed Diabetes in the U.S.
Ford, E. S. (2011) · Diabetes Care · doi:10.2337/dc10-2251 · Cited by 105
Effect of Olea europaea leaves extract on streptozotocin induced diabetes in male albino rats
Al-Attar, A. M., & Al‐Salmi, F. A. (2017) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2017.03.002 · Cited by 123
Skyler, J. S. (2009) · Diabetes Care · doi:10.2337/dc09-9031 · Cited by 100
Self-citationFritsche, A., Larbig, M., Owens, D., Häring, H. ‐., & on behalf of the GINGER study group (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01165.x · Cited by 102
Association of depression and diabetes complications and mortality: a population-based cohort study
Wu, C., Hsu, L. Y., & Wang, S. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796020000049 · Cited by 115
Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk
Gerich (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s8216 · Cited by 100
Vazquez-Benitez, G., Desai, J. R., Xu, S., Goodrich, G. K., Schroeder, E. B., Nichols, G. A., Segal, J., Butler, M. G., Karter, A. J., Steiner, J. F., et al. (2015) · Diabetes Care · doi:10.2337/dc14-1877 · Cited by 101
Vesa, C. M., Popa, L., Popa, A. R., Rus, M., Zaha, A. A., Bungau, S., Tit, D. M., Corb Aron, R. A., & Zaha, D. C. (2020) · Diagnostics · doi:10.3390/diagnostics10050314 · Cited by 96
Coronary Artery Revascularization in Patients With Diabetes Mellitus
Armstrong, E. J., Rutledge, J. C., & Rogers, J. H. (2013) · Circulation · doi:10.1161/circulationaha.113.002114 · Cited by 107
Schwartz, S. L. (2010) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2010.10.003 · Cited by 100
Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes
Lebovitz, H. E. (2011) · Diabetes Care · doi:10.2337/dc11-s225 · Cited by 115
Clinical Inertia as a Clinical Safeguard
Giugliano, D., & Esposito, K. (2011) · JAMA · doi:10.1001/jama.2011.490 · Cited by 98
Avdic, T., Franzén, S., Zarrouk, M., Acosta, S., Nilsson, P., Gottsäter, A., Svensson, A., Gudbjörnsdottir, S., & Eliasson, B. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007618 · Cited by 92
Association between hypoglycemia and dementia in patients with type 2 diabetes
Sheen, Y., & Sheu, W. H. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.004 · Cited by 105
Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data?
Gregg, L. P., & Hedayati, S. S. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.12.007 · Cited by 91
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus
Kirkman, M. S., Mahmud, H., & Korytkowski, M. T. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.002 · Cited by 95
Self-citationMetabolic Memory and Chronic Diabetes Complications: Potential Role for Epigenetic Mechanisms
Intine, R. V. A., & Sarras, M. P. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0302-7 · Cited by 97
Gallwitz, B., Böhmer, M., Segiet, T., Mölle, A., Milek, K., Becker, B., Helsberg, K., Petto, H., Peters, N., & Bachmann, O. (2011) · Diabetes Care · doi:10.2337/dc10-1900 · Cited by 88
Monnier, L., Colette, C., & Owens, D. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.014 · Cited by 91
the Shinken Database Study Group, Nakamura, M., Yamashita, T., Yajima, J., Oikawa, Y., Sagara, K., Koike, A., Kirigaya, H., Nagashima, K., Sawada, H., et al. (2010) · Hypertension Research · doi:10.1038/hr.2010.126 · Cited by 91
Pi-Sunyer, F. X. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.09.2056 · Cited by 86
Forst, T., Hanefeld, M., Jacob, S., Moeser, G., Schwenk, G., Pfützner, A., & Haupt, A. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112465442 · Cited by 85
Mikus, C. R., Oberlin, D. J., Libla, J., Boyle, L. J., & Thyfault, J. P. (2012) · Diabetologia · doi:10.1007/s00125-012-2490-8 · Cited by 85
Huang, O. S., Tay, W. T., Ong, P. G., Sabanayagam, C., Cheng, C.-Y., Tan, G. S., Cheung, G. C. M., Lamoureux, E. L., & Wong, T. Y. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-306492 · Cited by 84
Vascular Protection in Diabetic Stroke: Role of Matrix Metalloprotease-Dependent Vascular Remodeling
Elgebaly, M. M., Prakash, R., Li, W., Ogbi, S. N., Johnson, M. H., Mezzetti, E. M., Fagan, S. C., & Ergul, A. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.120 · Cited by 87
Monnier, L., & Colette, C. (2009) · Diabetes Care · doi:10.2337/dc09-s310 · Cited by 82
Williams, K. J., & Wu, X. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.004 · Cited by 87
The Early Treatment of Type 2 Diabetes
Pratley, R. E. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.06.007 · Cited by 109
Role of Bile Acid Sequestrants in the Treatment of Type 2 Diabetes
Handelsman, Y. (2011) · Diabetes Care · doi:10.2337/dc11-s237 · Cited by 81
Xiong, J., Wu, Z., Chen, C., Wei, Y. Q., & Guo, W. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.016 · Cited by 88
Lin, C.-C., Yang, C.-P., Li, C.-I., Liu, C.-S., Chen, C.-C., Lin, W.-Y., Hwang, K.-L., Yang, S.-Y., & Li, T.-C. (2014) · BMC Medicine · doi:10.1186/s12916-014-0165-7 · Cited by 80
An update on DPP-4 inhibitors in the management of type 2 diabetes
Cahn, A., Cernea, S., & Raz, I. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1257608 · Cited by 83
Diabetes & coronary heart disease: Current perspectives
Ali, M. K., Narayan, K. M. V., & Tandon, N. (2010) · Indian Journal of Medical Research · doi:10.4103/ijmr.2010_132_05_584 · Cited by 77
The Roles of Peroxisome Proliferator-Activated Receptors in the Metabolic Syndrome
Mansour, M. M. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-800101-1.00007-7 · Cited by 82
Bron, M., Marynchenko, M., Yang, H., Yu, A. P., & Wu, E. Q. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.01.2525 · Cited by 78
How to Manage Heart Failure With Preserved Ejection Fraction
Desai, A. S., Lam, C. S. P., McMurray, J. J. V., & Redfield, M. M. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.03.011 · Cited by 96
Naito, R., & Kasai, T. (2015) · World Journal of Cardiology · doi:10.4330/wjc.v7.i3.119 · Cited by 82
Lorusso, R., Gelsomino, S., Lucà, F., Cicco, G. D., Billè, G., Carella, R., Villa, E., Troise, G., Viganò, M., Banfı, C., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.025064 · Cited by 82
Derosa, G., & Maffioli, P. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.04.012 · Cited by 76
Doucet, J., Floch, J. P. L., Bauduceau, B., & Verny, C. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.07.001 · Cited by 91
Sex-gender-related therapeutic approaches for cardiovascular complications associated with diabetes
Campesi, I., Franconi, F., Seghieri, G., & Meloni, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.023 · Cited by 84
Walz, L., Pettersson, B., Rosenqvist, U., Deleskog, A., Journath, G., & Wändell, P. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s58781 · Cited by 75
Ceriello, A., Barkai, L., Christiansen, J. S., Czupryniak, L., Gomis, R., Harno, K., Kulzer, B., Ludvigsson, J., Némethyová, Z., Owens, D. R., et al. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.07.005 · Cited by 80
Yi, S., Park, S., Lee, Y., Park, H.-J., Balkau, B., & Yi, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-08498-6 · Cited by 81
Basu, S., Raghavan, S., Wexler, D. J., & Berkowitz, S. A. (2017) · Diabetes Care · doi:10.2337/dc17-2252 · Cited by 80
Schernthaner, G. (2010) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-010-0748-7 · Cited by 80
van Genugten, R. E., van Raalte, D. H., & Diamant, M. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01473.x · Cited by 73
Hirshberg, B., & Raz, I. (2011) · Diabetes Care · doi:10.2337/dc11-s202 · Cited by 76
Age-related differences in glycaemic control in diabetes
Selvin, E., & Parrinello, C. M. (2013) · Diabetologia · doi:10.1007/s00125-013-3078-7 · Cited by 82
Shafabakhsh, R., Mobini, M., Raygan, F., Aghadavod, E., Ostadmohammadi, V., Amirani, E., Mansournia, M. A., & Asemi, Z. (2020) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2020.09.029 · Cited by 81
Lian, F., Tian, J., Chen, X., Li, Z., Piao, C., Guo, J., Licheng, M., Zhao, L., Xia, C., Wang, C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130550 · Cited by 75
Moshapa, F. T., Riches‐Suman, K., & Palmer, T. M. (2019) · Cardiology Research and Practice · doi:10.1155/2019/9846312 · Cited by 79
Валерьевич, А. О., HARUTYUNYAN, G., Duplyakov, D. V., Константинова, Е. В., Konstantinova, N. N., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Sa, A., Alekyan, B. G., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6306 · Cited by 100
American Diabetes Association Indications for Statins in Diabetes
Eldor, R., & Raz, I. (2009) · Diabetes Care · doi:10.2337/dc09-s345 · Cited by 71
Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management
Khunti, K., Zaccardi, F., Amod, A., Aroda, V. R., Montoya, P. A., Colagiuri, S., Mohan, V., & Chan, J. C. N. (2024) · Diabetologia · doi:10.1007/s00125-024-06254-w · Cited by 91
The glucose triad and its role in comprehensive glycaemic control: current status, future management
Ceriello, A. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02517.x · Cited by 78
Glycemic Control and Risk of Cardiovascular Disease Hospitalization and All-Cause Mortality
Nichols, G. A., Joshua-Gotlib, S., & Parasuraman, S. V. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.04.031 · Cited by 75
Bianchi, C., & Prato, S. D. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.432 · Cited by 70
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Intine, R. V. A., Olsen, A. S., & Sarras, M. P. (2013) · Journal of Visualized Experiments · doi:10.3791/50232 · Cited by 82
Type 2 Diabetes: Assessing the Relative Risks and Benefits of Glucose-lowering Medications
Bergenstal, R. M., Bailey, C. J., & Kendall, D. M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.07.017 · Cited by 76
Self-citationBlonde, L. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.005 · Cited by 81
Coronary Artery Disease and Diabetes Mellitus
Aronson, D., & Edelman, E. R. (2015) · Heart Failure Clinics · doi:10.1016/j.hfc.2015.08.010 · Cited by 74
Egger, A., Niederseer, D., Diem, G., Finkenzeller, T., Ledl-Kurkowski, E., Forstner, R., Pirich, C., Patsch, W., Weitgasser, R., & Niebauer, J. (2013) · European Journal of Preventive Cardiology · doi:10.1177/2047487312450132 · Cited by 67
GHb Level and Subsequent Mortality Among Adults in the U.S.
Saydah, S., Tao, M., Imperatore, G., & Gregg, E. (2009) · Diabetes Care · doi:10.2337/dc09-0117 · Cited by 67
Variability in hemoglobin A1c predicts all-cause mortality in patients with type 2 diabetes
Ma, W.-Y., Li, H., Pei, D., Hsia, T., Lu, K., Tsai, L., Wei, J., & Su, C. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.03.028 · Cited by 70
Maraschin, J. D. F. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5441-0_2 · Cited by 89
Hypoglycemia-associated autonomic failure in diabetes
Cryer, P. E. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53491-0.00023-7 · Cited by 74
Dailey, G. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.025 · Cited by 66
NOX4 Pathway as a Source of Selective Insulin Resistance and Responsiveness
Wu, X., & Williams, K. J. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.244525 · Cited by 67
Fonville, S., Zandbergen, A. A. M., Koudstaal, P. J., & den Hertog, H. M. (2014) · Cerebrovascular Diseases · doi:10.1159/000360810 · Cited by 65
Insulin Treatment Attenuates Decline of Muscle Mass in Japanese Patients with Type 2 Diabetes
Bouchi, R., Fukuda, T., Takeuchi, T., Nakano, Y., Murakami, M., Minami, I., Izumiyama, H., Hashimoto, K., Yoshimoto, T., & Ogawa, Y. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0251-x · Cited by 64
Metabolic memory: a vascular perspective
Jax, T. W. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-51 · Cited by 72
Schernthaner, G., Durán‐Garcia, S., Hanefeld, M., Langslet, G., Niskanen, L., Östgren, C. J., Malvolti, E., & Hardy, E. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12461 · Cited by 64
Metadata
- Authors
- Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., & Sherwin, R. S.
- Affiliations
- University of Miami (US)
- Park Nicollet Clinic (US)
- Northwestern University (US)
- University of North Carolina at Chapel Hill (US)
- University of California, San Francisco (US)
- University of Bristol (GB)
- American Diabetes Association (US)
- Saint Luke's Hospital (US)
- Carl T. Hayden Veterans Affairs Medical Center (US)
- Yale University (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-01-01
- Volume
- 32
- Issue
- 1
- Pages
- 187-192
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2606812
- OpenAlex
- W2181092548
- Cited by
- 881
- References
- 22
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 13 · 2023: 24 · 2022: 23 · 2021: 32 · 2020: 37 · 2019: 40 · 2018: 43 · 2017: 46 · 2016: 53 · 2015: 70 · 2014: 56 · 2013: 68 · 2012: 101
- FWCI
- 62.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- Sanofi
- Edwards Lifesciences
- Osiris Therapeutics
- Insulet Corporation
- MannKind Corporation
- Halozyme
- Dexcom
- Tandem Diabetes Care
- Daiichi-Sankyo
- Novo Nordisk
- Pfizer Pharmaceuticals
- Daiichi Sankyo Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- tight glycemic control, cardiovascular events, type 1 diabetes, type 2 diabetes, microvascular complications, HbA1c targets, ACCORD trial, ADVANCE trial, Diabetes Control and Complications Trial, UKPDS, diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, cardiovascular risk
- MeSH terms
- Adult, Aged, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Homeostasis, Humans, Hyperglycemia, Middle Aged, Risk Factors, Sensitivity and Specificity, Randomized Controlled Trials as Topic, Risk Assessment, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.